Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay

Acta Pharmacologica Sinica

Volumn 35, Issue 8, 2014, Pages 1082-1092

  Ji, Jin Zi ^a   Lao, Ke Jing ^a   Hu, Jie ^a   Pang, Tao ^a   Jiang, Zhen Zhou ^a   Yuan, Hao Liang ^a   Miao, Jing Shan ^a   Chen, Xin ^a   Ning, Shan Shan ^a   Xiang, Hua ^a   Guo, Yu Meng ^a   Yan, Ming ^a   Zhang, Lu Yong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aromatase; Breast cancer; Drug discovery; Highthroughput screening; Homogeneous time resolved fluorescence assay; Imidazolyl quinoline; Molecular docking; Triptoquinone A

Indexed keywords

AMINO ACID; AROMATASE INHIBITOR; BIOCHANIN A; CATION; FLAVONE DERIVATIVE; LETROZOLE; QUINOLINE DERIVATIVE; TRIPTERYGIUM WILFORDII EXTRACT; UNCLASSIFIED DRUG; XHN 22; XHN 26; XHN 27; AROMATASE; FLAVONOID; MOLECULAR LIBRARY;

ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME MECHANISM; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HOMOGENEOUS TIME RESOLVED FLUORESCENCE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; PROTEIN INTERACTION; TRIPTERYGIUM WILFORDII; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; SPECTROFLUOROMETRY; TUMOR CELL LINE;

AROMATASE; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLAVONOIDS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR DOCKING SIMULATION; QUINOLINES; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE;

EID: 84905663711     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.53     Document Type: Article

References (52)

1. Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 2008; 14: 428-34.
2. Tian CY, Hu CQ, Xu G, Song HY. Assessment of estrogenic activity of natural compounds using improved E-screen assay. Acta Pharmacol Sin 2002; 23: 572-6.
3. Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 2007; 28: 1466-75.
4. Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR, et al. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989; 264: 19385-91.
5. Chen SA, Besman MJ, Sparkes RS, Zollman S, Klisak I, Mohandas T, et al. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA 1988; 7: 27-38.
6. Hong Y, Li H, Yuan YC, Chen S. Sequence-function correlation of aromatase and its interaction with reductase. J Steroid Biochem Mol Biol 2010; 118: 203-6.
7. Cheng HH, Hu XJ, Ruan QR. Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol Sin 2009; 30: 42-53.
8. Feuillan P, Merke D, Leschek EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 1999; 6: 303-6.
9. Roth C, Freiberg C, Zappel H, Albers N. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 Suppl 3: 945-8.
10. Gao Q, Patani N, Dunbier AK, Ghazoui Z, Zvelebil M, Martin LA, et al. Effect of aromatase inhibition on functional gene modules in oestrogen receptor positive breast cancer and their relationship with antiproliferative response. Clin Cancer Res 2014; 20: 2485-94.
11. Henry NL, Conlon A, Kidwell KM, Griffith K, Smerage JB, Schott AF, et al. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer. J Pain 2014; 15: 468-75.
12. Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim Biophys Acta 2002; 1587: 326-37.
13. Dutta U, Pant K. Aromatase inhibitors: past, present and future in breast cancer therapy. Med Oncol 2008; 25: 113-24.
14. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, et al. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009; 18: S1-S11.
15. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, et al. Patientreported outcomes in women with breast cancer enrolled in a dualcenter, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 2014; 120: 381-9.
16. Pouliot L, Schneider M, DeCristofaro M, Samadfam R, Smith SY, Beckman DA. Assessment of a nonsteroidal aromatase inhibitor, letrozole, in juvenile rats. Birth Defects Res B Dev Reprod Toxicol 2013; 98: 374-90.
17. Bian C, Zhao Y, Guo Q, Xiong Y, Cai W, Zhang J. Aromatase inhibitor letrozole downregulates steroid receptor coactivator-1 in specific brain regions that primarily related to memory, neuroendocrine and integration. J Steroid Biochem Mol Biol 2014; 141C: 37-43.
18. Balunas MJ, Kinghorn AD. Natural compounds with aromatase inhibitory activity: an update. Planta Med 2010; 76: 1087-93.
19. Li QY, Chen L, Zhu YH, Zhang M, Wang YP, Wang MW. Involvement of estrogen receptor-beta in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation. Acta Pharmacol Sin 2011; 32: 433-40.
20. Wang Y, Man Gho W, Chan FL, Chen S, Leung LK. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr 2008; 99: 303-10.
21. Lephart ED, Simpson ER. Assay of aromatase activity. In: Waterman MR, Johnson EF, editors. Methods in enzymology. Orlando: Academic Press; 1991. p 477-83.
22. Ros AF, Franco AM, Groothuis TG. Experience modulates both aromatase activity and the sensitivity of agonistic behaviour to testosterone in black-headed gulls. Physiol Behav 2009; 97: 30-5.
23. Trosken ER, Fischer K, Volkel W, Lutz WK. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology 2006; 219: 33-40.
24. Stresser DM, Turner SD, McNamara J, Stocker P, Miller VP, Crespi CL, et al. A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem 2000; 284: 427-30.
25. Chen S, Chen LL, Luo HB, Sun T, Chen J, Ye F, et al. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. Acta Pharmacol Sin 2005; 26: 99-106.
26. Mao WF, Shao MH, Gao PT, Ma J, Li HJ, Li GL, et al. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin 2012; 33: 1311-8.
27. Ha T, Enderle T, Ogletree DF, Chemla DS, Selvin PR, Weiss S. Probing the interaction between two single molecules: fluorescence resonance energy transfer between a single donor and a single acceptor. Proc Natl Acad Sci U S A 1996; 93: 6264-8.
28. Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B. HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr Chem Genomics 2009; 3: 22-32.
29. Chen YC, Liu YL, Li FY, Chang CI, Wang SY, Lee KY, et al. Antcin A, a steroid-like compound from Antrodia camphorata, exerts antiinflammatory effect via mimicking glucocorticoids. Acta Pharmacol Sin 2011; 32: 904-11.
30. Ma HR, Wang J, Qi HX, Gao YH, Pang LJ, Yang Y, et al. Assessment of the estrogenic activities of chickpea (Cicer arietinum L) sprout isoflavone extract in ovariectomized rats. Acta Pharmacol Sin 2013; 34: 380-6.
31. Chen CY, Chang YH, Bau DT, Huang HJ, Tsai FJ, Tsai CH, et al. Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis. Acta Pharmacol Sin 2009; 30: 1186-94.
32. Dowsett M, Macaulay V, Gledhill J, Ryde C, Nicholls J, Ashworth A, et al. Control of aromatase in breast cancer cells and its importance for tumor growth. J Steroid Biochem Mol Biol 1993; 44: 605-9.
33. Voytik-Harbin SL, Brightman AO, Waisner B, Lamar CH, Badylak SF. Application and evaluation of the alamarBlue assay for cell growth and survival of fibroblasts. In Vitro Cell Dev Biol Anim 1998; 34: 239-46.
34. Chen CC, Chen HL, Hsieh CW, Yang YL, Wung BS. Upregulation of NF E2-related factor-2-dependent glutathione by carnosol provokes a cytoprotective response and enhances cell survival. Acta Pharmacol Sin 2011; 32: 62-9.
35. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
36. Kim YW, Hackett JC, Brueggemeier RW. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem 2004; 47: 4032-40.
37. Wood PM, Woo LWL, Humphreys A, Chander SK, Purohit A, Reed MJ, et al. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol 2005; 94: 123-30.
38. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990; 37: 1021-7.
39. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009; 457: 219-23.
40. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-7.
41. Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat 2009; 114: 495-501.
42. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95: 2006-16.
43. McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multicentre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007; 43: 2523-31.
44. Zhang J, Jiang Z, Zhang L. Effect of triptolide on aromatase activity in human placental microsomes and human placental JEG-3 cells. Arzneimittelforschung 2011; 61: 727-33.
45. Hecker M, Newsted JL, Murphy MB, Higley EB, Jones PD, Wu R, et al. Human adrenocarcinoma (H295R) cells for rapid in vitro determination of effects on steroidogenesis: hormone production. Toxicol Appl Pharmacol 2006; 217: 114-24.
46. Wood PM, Woo LW, Humphreys A, Chander SK, Purohit A, Reed MJ, et al. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol 2005; 94: 123-30.
47. Gervais M, Tan L. 6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells. Anticancer Res 1993; 13: 383-8.
48. Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998; 67: 293-304.
49. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006; 66: 11207-13.
50. Sadekova SI, Tan L, Chow TY. Identification of the aromatase in the breast carcinoma cell lines T47D and MCF-7. Anticancer Res 1994; 14: 507-11.
51. Ryde CM, Nicholls JE, Dowsett M. Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines. Cancer Res 1992; 52: 1411-5.
52. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005; 94: 461-7.